FibroBiologics Appoints Mark C. Andersen as Chief Financial Officer

Experienced financial executive joins the executive team at Houston-based company HOUSTON, June 2, 2022 /PRNewswire/ – FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today announced the appointment of Mark C. Andersen MBA, CFA, CPA, as Chief Financial Officer. Mr. Andersen will serve as a key member of […]

FibroBiologics Presents Preclinical Data at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting

HOUSTON, May 31, 2022 – FibroBiologics, a clinical-stage biotechnology company developing fibroblast-based therapeutic cures for chronic diseases, will present preclinical and safety-centered limited clinical trial data for the single-dose infusion of tolerogenic human dermal fibroblasts (HDFs) data at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting being held in person from June 1 – […]

FibroBiologics Adds Microbiologist Kathleen “Kate” Rubins, Ph.D. to Scientific Advisory Board

Expert in Infectious Disease Joins World-Renowned Scientists Advising Houston Company on Development of Fibroblast Cell-Based Therapeutics for a Wide Range of Chronic Diseases HOUSTON, March 10, 2022 – FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today announced the addition of Kathleen “Kate” Rubins, Ph.D., to its Scientific […]